Literature DB >> 20720069

Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis.

Michele Di Martino1, Daniele Marin, Antonino Guerrisi, Mahbubeh Baski, Francesca Galati, Massimo Rossi, Stefania Brozzetti, Raffaele Masciangelo, Roberto Passariello, Carlo Catalano.   

Abstract

PURPOSE: To prospectively compare gadoxetate disodium-enhanced magnetic resonance (MR) imaging with multiphasic 64-section multidetector computed tomography (CT) in the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis.
MATERIALS AND METHODS: Institutional review board approval and informed patient consent were obtained for this prospective study. Fifty-eight patients (39 men, 19 women; mean age, 63 years; age range, 35-84 years) underwent gadoxetate disodium-enhanced MR imaging and multiphasic 64-section multidetector CT. The imaging examinations were performed within 30 days of each other. The two sets of images were qualitatively analyzed in random order by three independent readers in a blinded and retrospective fashion. Using strict diagnostic criteria for HCC, readers classified all detected lesions with use of a four-point confidence scale. The reference standard was a combination of pathologic proof, conclusive imaging findings, and substantial tumor growth at follow-up CT or MR imaging (range of follow-up, 90-370 days). The diagnostic accuracy, sensitivity, and positive predictive value were compared between the two image sets. Interreader variability was assessed. The accuracy of each imaging method was determined by using an adjusted modified chi(2) test.
RESULTS: Eighty-seven HCCs (mean size +/- standard deviation, 1.8 cm +/- 1.5; range, 0.3-7.0 cm) were confirmed in 42 of the 58 patients. Regardless of lesion size, the average diagnostic accuracy and sensitivity for all readers were significantly greater with gadoxetate disodium-enhanced MR imaging (average diagnostic accuracy: 0.88, 95% confidence interval [CI]: 0.80, 0.97; average sensitivity: 0.85, 95% CI: 0.74, 0.96) than with multidetector CT (average diagnostic accuracy: 0.74, 95% CI: 0.65, 0.82; average sensitivity: 0.69, 95% CI: 0.59, 0.79) (P < .001 for each). No significant difference in positive predictive value was observed between the two image sets for each reader. Interreader agreement was good to excellent.
CONCLUSION: Compared with multiphasic 64-section multidetector CT, gadoxetate disodium-enhanced MR imaging yields significantly higher diagnostic accuracy and sensitivity in the detection of HCC in patients with cirrhosis. (c) RSNA, 2010.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20720069     DOI: 10.1148/radiol.10091334

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  80 in total

Review 1.  [Combined PET-MRI of the abdomen].

Authors:  Tibor Vag; M Eiber; M Schwaiger
Journal:  Radiologe       Date:  2015-12       Impact factor: 0.635

2.  Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Junji Shiraishi; Kazuhiro Saito; Junichi Taira; Toru Saguchi; Yasuharu Imai
Journal:  Eur Radiol       Date:  2012-01-24       Impact factor: 5.315

3.  Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI.

Authors:  H Rhee; M-J Kim; M-S Park; K A Kim
Journal:  Br J Radiol       Date:  2012-05-02       Impact factor: 3.039

Review 4.  Solid liver masses: approach to management from the standpoint of a radiologist.

Authors:  Robert Garrett
Journal:  Curr Gastroenterol Rep       Date:  2013-12

Review 5.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

Review 6.  Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.

Authors:  Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-15

7.  Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.

Authors:  Antonio Orlacchio; Fabrizio Chegai; Sebastiano Fabiano; Stefano Merolla; Valentina Funel; Francesca Di Giuliano; Matteo Manuelli; Giuseppe Tisone; Simona Francioso; Mario Angelico; Giampiero Palmieri; Giovanni Simonetti
Journal:  Radiol Med       Date:  2016-04-21       Impact factor: 3.469

8.  The expression of transporter OATP2/OATP8 decreases in undetectable hepatocellular carcinoma by Gd-EOB-MRI in the explanted cirrhotic liver.

Authors:  Masaaki Hidaka; Mitsuhisa Takatsuki; Sadayuki Okudaira; Akihiko Soyama; Izumi Muraoka; Takayuki Tanaka; Izumi Yamaguchi; Takanobu Hara; Hisamitsu Miyaaki; Tatsuki Ichikawa; Tomayoshi Hayashi; Ichiro Sakamoto; Kazuhiko Nakao; Tamotsu Kuroki; Takashi Kanematsu; Susumu Eguchi
Journal:  Hepatol Int       Date:  2012-06-24       Impact factor: 6.047

Review 9.  Magnetic resonance imaging of the cirrhotic liver: An update.

Authors:  Agnes Watanabe; Miguel Ramalho; Mamdoh AlObaidy; Hye Jin Kim; Fernanda G Velloni; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-03-27

10.  Gadoxetic acid-enhanced MRI for T-staging of gallbladder carcinoma: emphasis on liver invasion.

Authors:  J Hwang; Y K Kim; D Choi; H Rhim; W J Lee; S S Hong; H-J Kim; Y-W Chang
Journal:  Br J Radiol       Date:  2013-11-28       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.